Solid Biosciences (SLDB) Income from Non-Controlling Interests (2017)
Solid Biosciences' (SLDB) quarterly Income from Non-Controlling Interests came in at -$1.1 million in Q1 2017.
Solid Biosciences (SLDB) Income from Non-Controlling Interests (2017) Analysis & Trends
Solid Biosciences has disclosed Income from Non-Controlling Interests across 1 years of filings, most recently posting -$1.1 million for Q1 2017.
- Income from Non-Controlling Interests for Q1 2017 came in at -$1.1 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2017 was -$1.1 million (changed N/A YoY), and the FY2017 annual result was -$1.1 million, up 52.55% from the prior year.
- Income from Non-Controlling Interests came in at -$1.1 million for Q1 2017 at Solid Biosciences.
- In the past five years, Income from Non-Controlling Interests ranged from a high of -$1.1 million in Q1 2017 to a low of -$1.1 million in Q1 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Solid Biosciences | 789.54 Mn | 408.86 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2017 | -1.06 Mn |